71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
January 2003 in “Journal of Clinical Dermatology” Cyclosporin promotes hair growth by boosting cell growth and reducing cell death.
1 citations
,
May 2022 in “The FASEB journal” The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.
29 citations
,
July 2014 in “PLoS ONE” Inactivating β-catenin is essential for chick retina regeneration.
10 citations
,
June 2022 in “Frontiers in Immunology” Fucoidan reduces bone cell formation by affecting T-cell activity.
4 citations
,
January 2023 in “Proteomes” Tumor proteins can both promote and suppress cancer, depending on the situation.
November 2018 in “Zenodo (CERN European Organization for Nuclear Research)” Silver nanoparticles may reduce chemotherapy side effects and improve cancer treatment.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
January 2023 in “Open journal of pediatrics” A 7-month-old girl with a rare skin disorder died because diagnosis was delayed.
1 citations
,
April 2015 in “Nasza Dermatologia Online” Dermatologists should be involved in the care of hematology patients due to common skin issues.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
39 citations
,
September 2018 in “American Journal of Medical Genetics Part A” A new genetic mutation in the ODC1 gene causes developmental delay and other symptoms in a young girl.
70 citations
,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
ANE syndrome is caused by a mutation in the RBM28 protein that disrupts ribosome assembly.
June 1987 in “Pediatric Neurology Briefs” Biotinidase deficiency can cause symptoms like sleepiness, hair loss, and seizures.
87 citations
,
February 2019 in “Tissue Engineering Part B Reviews” Platelet-rich plasma can effectively treat and prevent tissue infections.
5 citations
,
April 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” A new therapy for a skin blistering condition has not been developed yet.
April 2023 in “World Journal of Advanced Research and Reviews” Frequent blood transfusions in beta thalassemia can lead to thyroid problems.
November 2025 in “American Journal of Tropical Medicine and Hygiene” Low platelet count and hematocrit may increase the risk of hair loss in dengue fever patients.
21 citations
,
January 1999 in “Molecular and Cellular Biochemistry” Niacin deficiency makes rats more sensitive to cancer-causing chemicals.
74 citations
,
January 2014 in “Journal of Investigative Dermatology” High kallistatin levels in diabetics worsen wound healing by blocking important cell signals.
May 2015 in “Cancer Research” A new treatment may prevent hair loss from chemotherapy by normalizing scalp cell death and reducing inflammation.
August 2024 in “Journal of the Association of Physicians of India” Adding vitamin B12 to food like salt can effectively improve vitamin levels in rural areas.
Skin tumor cells in patients with tuberous sclerosis have higher levels of a protein called cathepsin B.
December 2024 in “International Journal of Molecular Sciences” Platelet-rich fibrin may help reduce nonmelanoma skin cancer cell growth.
1 citations
,
September 2017 C-scores can help predict gain-of-function and loss-of-function mutations.
1 citations
,
November 1991 in “PubMed” Immunoadsorption successfully treated a man's resistant polymyositis.
More research is needed to understand chemotherapy-induced hair loss and its phases.
1 citations
,
January 2025 in “Pediatria i Medycyna Rodzinna” Accurate diagnosis and zinc supplements can improve life quality in acrodermatitis enteropathica, even with normal zinc levels.
98 citations
,
March 2019 in “Frontiers in immunology” Damaging mutations in NFKB2 cause a severe and distinct form of primary immunodeficiency with early-onset and often ACTH-deficiency.